Hepion Pharmaceuticals‘ CRV431 lowers the production of fibrosis-associated proteins in a variety of cell types, including lung cells,…
Articles by Marisa Wexler, MS
A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases…
Galapagos NVÂ announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of oral GLPG1205 in…
Use of INOpulse — inhaled nitric oxide — increased physical activity and improved patient-reported outcomes in people with…
The molecular clockwork that regulates circadian rhythms can become dysregulated in the lungs of people with pulmonary fibrosis, promoting processes…
The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung…
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in…
Ofev (nintedanib) slows the rate of decline in lung function in people with interstitial lung diseases (ILDs) associated with…
The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and…
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is…